Allegheny Health Network Partners with The START Center to Enhance Cancer Trial Accessibility#United_States#Pittsburgh#Cancer_Trials#START_Center#AHN
Allegheny Health Network Partners with The START Center to Enhance Cancer Trial Accessibility
A strategic partnership between Allegheny Health Network and The START Center aims to increase access to early-phase cancer trials for patients in Western Pennsylvania.
third-news.com
August 25, 2026 at 12:15 PM
Allegheny Health Network Partners with The START Center to Enhance Cancer Trial Accessibility#United_States#Pittsburgh#Cancer_Trials#START_Center#AHN
Partner Therapeutics Unveils Promising Findings of Zenocutuzumab for Cholangiocarcinoma Patients#United_States#Massachusetts#Cancer_Trials#Zenocutuzumab#Partner_Therapeutics
Partner Therapeutics Unveils Promising Findings of Zenocutuzumab for Cholangiocarcinoma Patients
Partner Therapeutics announces the publication of significant findings regarding Zenocutuzumab's efficacy in treating patients with NRG1+ cholangiocarcinoma, marking a key milestone in cancer therapy.
third-news.com
July 2, 2026 at 10:35 AM
Partner Therapeutics Unveils Promising Findings of Zenocutuzumab for Cholangiocarcinoma Patients#United_States#Massachusetts#Cancer_Trials#Zenocutuzumab#Partner_Therapeutics
GlycoNex Achieves PMDA Approval for First-in-Human Trial of GNX1021 Targeting Gastrointestinal Cancers#Japan#New_Taipei_City#GlycoNex#Cancer_Trials#GNX1021
GlycoNex Achieves PMDA Approval for First-in-Human Trial of GNX1021 Targeting Gastrointestinal Cancers
GlycoNex, Inc. marks a significant milestone with PMDA approval for GNX1021, initiating its first human trial targeting advanced gastrointestinal cancers.
third-news.com
April 14, 2026 at 12:15 PM
GlycoNex Achieves PMDA Approval for First-in-Human Trial of GNX1021 Targeting Gastrointestinal Cancers#Japan#New_Taipei_City#GlycoNex#Cancer_Trials#GNX1021
First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034#United_States#IDEAYA_Biosciences#South_San_Francisco#Cancer_Trials#IDE034
First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034
IDEAYA Biosciences has announced the enrollment of its first patient in the Phase 1 trial of IDE034, targeting specific types of cancers with promising results.
third-news.com
February 25, 2026 at 11:13 AM
First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034#United_States#IDEAYA_Biosciences#South_San_Francisco#Cancer_Trials#IDE034
Northwell Health Launches State-of-the-Art Cancer Trial Center in Long Island#United_States#Cancer_Trials#START_Center#Northwell_Health#Lake_Success
Northwell Health Launches State-of-the-Art Cancer Trial Center in Long Island
Northwell Health and START Center for Cancer Research unveil an advanced clinical trial center in Long Island, expanding access to cutting-edge cancer treatments.
third-news.com
December 17, 2025 at 2:24 PM
Northwell Health Launches State-of-the-Art Cancer Trial Center in Long Island#United_States#Cancer_Trials#START_Center#Northwell_Health#Lake_Success
HopeAI Revolutionizes Cancer Drug Trials Using AI-Generated Synthetic Data at ASCO 2025#United_States#New_York#Cancer_Trials#ASCO_2025#HopeAI
HopeAI Revolutionizes Cancer Drug Trials Using AI-Generated Synthetic Data at ASCO 2025
HopeAI showcases its innovative application of AI-generated synthetic data to enhance the efficiency of cancer drug trials at ASCO 2025.
third-news.com
August 13, 2025 at 6:11 PM
HopeAI Revolutionizes Cancer Drug Trials Using AI-Generated Synthetic Data at ASCO 2025#United_States#New_York#Cancer_Trials#ASCO_2025#HopeAI
START Launches Hope Hub for Enhanced Access to Cancer Trial Information#United_States#San_Antonio#Cancer_Trials#START_Center#Hope_Hub
START Launches Hope Hub for Enhanced Access to Cancer Trial Information
The START Center introduces the Hope Hub, a revolutionary platform aimed at improving access to cancer clinical trials for patients, physicians, and advocacy groups. This initiative promises to connect communities effectively.
third-news.com
June 18, 2025 at 12:14 PM
START Launches Hope Hub for Enhanced Access to Cancer Trial Information#United_States#San_Antonio#Cancer_Trials#START_Center#Hope_Hub
Novita Pharmaceuticals Presents Exciting Phase 2 Trial Data for NP-G2-044 in Metastatic Solid Tumors at ASCO 2025#USA#New_York#Cancer_Trials#NP-G2-044#Novita
Novita Pharmaceuticals Presents Exciting Phase 2 Trial Data for NP-G2-044 in Metastatic Solid Tumors at ASCO 2025
At the 2025 ASCO Annual Meeting, Novita Pharmaceuticals revealed encouraging findings from its Phase 2 NP-G2-044 trial for advanced solid tumors.
third-news.com
May 22, 2025 at 9:11 PM
Novita Pharmaceuticals Presents Exciting Phase 2 Trial Data for NP-G2-044 in Metastatic Solid Tumors at ASCO 2025#USA#New_York#Cancer_Trials#NP-G2-044#Novita
Leukemia & Lymphoma Society Opens Grant Applications for Enhanced Cancer Trial Access#USA#Cancer_Trials#Leukemia_Society#Equity_Research#RYE_BROOK,_NY
Leukemia & Lymphoma Society Opens Grant Applications for Enhanced Cancer Trial Access
The Leukemia & Lymphoma Society has launched a new grant application process aimed at improving access to cancer clinical trials for underrepresented groups. Up to $2.5 million is available per study.
third-news.com
May 22, 2025 at 1:21 PM
Leukemia & Lymphoma Society Opens Grant Applications for Enhanced Cancer Trial Access#USA#Cancer_Trials#Leukemia_Society#Equity_Research#RYE_BROOK,_NY
Trial Library Collaboration with Texas Oncology Revolutionizes Access to Clinical Trials for Cancer Patients#United_States#San_Francisco#Cancer_Trials#Trial_Library#Texas_Oncology
Trial Library Collaboration with Texas Oncology Revolutionizes Access to Clinical Trials for Cancer Patients
Trial Library partners with Texas Oncology to improve access to clinical trials, leveraging technology to guide patients through vital cancer research.
third-news.com
May 20, 2025 at 12:40 PM
Trial Library Collaboration with Texas Oncology Revolutionizes Access to Clinical Trials for Cancer Patients#United_States#San_Francisco#Cancer_Trials#Trial_Library#Texas_Oncology
AI Innovations Revolutionizing Healthcare: From Diagnostics to Treatment#Canada#Vancouver#AI_in_Healthcare#Avant_Technologies#Cancer_Trials
AI Innovations Revolutionizing Healthcare: From Diagnostics to Treatment
Artificial intelligence is rapidly transforming healthcare, enhancing diagnostics and personalized care. Learn how companies like Avant Technologies are leading this change.
third-news.com
May 20, 2025 at 11:47 AM
AI Innovations Revolutionizing Healthcare: From Diagnostics to Treatment#Canada#Vancouver#AI_in_Healthcare#Avant_Technologies#Cancer_Trials
Intensity Therapeutics Initiates $2.35 Million Public Offering for Cancer Treatment Advancements#United_States#Public_Offering#Intensity_Therapeutics#Shelton#Cancer_Trials
Intensity Therapeutics Initiates $2.35 Million Public Offering for Cancer Treatment Advancements
Intensity Therapeutics has announced a $2.35 million public offering aimed at furthering its innovative cancer therapies. This funding will support ongoing clinical trials and patient enrollments.
third-news.com
April 25, 2025 at 12:09 PM
Intensity Therapeutics Initiates $2.35 Million Public Offering for Cancer Treatment Advancements#United_States#Public_Offering#Intensity_Therapeutics#Shelton#Cancer_Trials
Taiho Oncology's Decitabine and Cedazuridine to Feature in NIH Precision Medicine Trials for Cancer#United_States#Princeton#Precision_Medicine#Taiho_Oncology#Cancer_Trials
Taiho Oncology's Decitabine and Cedazuridine to Feature in NIH Precision Medicine Trials for Cancer
Taiho Oncology announces that its oral treatments, decitabine and cedazuridine, will be used in NIH trials for myelodysplastic syndromes and AML.
third-news.com
January 14, 2025 at 2:35 PM
Taiho Oncology's Decitabine and Cedazuridine to Feature in NIH Precision Medicine Trials for Cancer#United_States#Princeton#Precision_Medicine#Taiho_Oncology#Cancer_Trials